Disclosure of Adverse Clinical Trial Results—Should Legal Immunity Be Granted to Drug Companies?

ISSN： 1536-0075

Source： American Journal of Bioethics, Vol.9, Iss.8, 2009-08, pp. : 45-47

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Respecting Participant Autonomy and the Disclosure of Clinical Trial Results

By Oakley Justin

American Journal of Bioethics, Vol. 9, Iss. 8, 2009-08 ,pp. : 38-38

Routledge Ltd

Access to resources Recommend Favorite

The Duty to Disclose Adverse Clinical Trial Results

By Liao S. Matthew Sheehan Mark Clarke Steve

American Journal of Bioethics, Vol. 9, Iss. 8, 2009-08 ,pp. : 24-32

Routledge Ltd

Access to resources Recommend Favorite

The Duty to Disclose (Even More) Adverse Clinical Trial Results

By Hassoun Nicole

American Journal of Bioethics, Vol. 9, Iss. 8, 2009-08 ,pp. : 33-34

Routledge Ltd

Access to resources Recommend Favorite

Enhancing Informed Consent in Clinical Trials and Exploring Resistances to Disclosing Adverse Clinical Trial Results

By Banja John Dunlop Boadie

American Journal of Bioethics, Vol. 9, Iss. 8, 2009-08 ,pp. : 39-41

Routledge Ltd

Access to resources Recommend Favorite

Improving Subject Recruitment By Maintaining Truly Informed Consent: A Practical Benefit of Disclosing Adverse Clinical Trial Results

By Shah Kavita Batzer Frances

American Journal of Bioethics, Vol. 9, Iss. 8, 2009-08 ,pp. : 36-37

Routledge Ltd

Access to resources Recommend Favorite